B O O K - American College of Rheumatology

wednesday
Upon completion of this session, participants should be able to:
• define the state of the evidence regarding physical activity in
adults with arthritis living in rural communities
• describe the development of a community-based approach
to learn about the levels of physical activity in a rural
environment in persons with arthritis
• examine perceived barriers/facilitators of physical activity in
persons with arthritis in rural communities
• identify benefits of physical activity in this subpopulation
B308
Using Pharmacogenomics to Improve Therapy for
Pediatric Patients P/C PS
Moderator: Bernadette McNally, MS, PAC; University of Utah;
Salt Lake City, UT
Speaker: Mara L. Becker, MD; Children’s Mercy Hospital; Kansas
City, MO
Session Overview:
In the emerging field of personalized medicine, it is important to
recognize that there is significant variability in drug response and
toxicity between adults and children. Targeted therapy-based on
age, genetics and development of the child may be the future
of prescribing medications for rheumatic disease for children,
specifically methotrexate. Ontogeny, the normal developmental
process may affect aspects of pharmacological response in
children including drug absorption, distribution, metabolism and
excretion. Developmental expression of different pathways at
different times may lead to variability in medication response.
Upon completion of this session, participants should be able to:
• describe differences in disease expression and drug response
in pediatric patients
• define what makes children different, including developmental
pharmacokinetics, pharmacogenetics in children and the role
of ontogeny
• summarize new pharmacogenomic data in commonly
used medications in pediatrics and identify gaps in current
knowledge
ACR Meet the Professor Sessions
7:45 - 9:15 am
Admission to each Meet the Professor session requires a
separate registration and ticket. To verify which session you
registered for, check to make sure the registration code on your
ticket matches the code listed below in parentheses.
B207
Adult Inflammatory Myopathy (061)
Speaker: Mary E. Cronin, MD; Medical College of Wisconsin;
Milwaukee, WI
Upon completion of this session, participants should be able to:
• discuss diagnostic pearls for the evaluation of someone
suspected of having an inflammatory myopathy
• discuss the treatment paradigm for inflammatory myopathies
B208
Crystal: Management of Gout (062) PS
Speaker: Hyon K. Choi, MD, DrPH; University of British Columbia;
Vancouver, BC, Canada
Upon completion of this session, participants should be able to:
• discuss the management of gout in patients with renal
insufficiency or organ transplants
• identify strategies to treat patients who are intolerant of
approved therapies
• cite agents in development for the treatment of
hyperuricemia and gout
B209
Pediatrics: Spondyloarthritis in Children (063) P
Speaker: Shirley Tse, MD; Hospital for Sick Children; Toronto, ON,
Canada
Upon completion of this session, participants should be able to:
• describe differences between spondylarthritis in children and
adults
• discuss the approach to diagnosis and treatment of children
with spondylarthritis
B210
Pregnancy in Rheumatic Diseases (064)
Speaker: Megan E.B. Clowse, MD, MPH; Duke University Medical
Center; Durham, NC
Upon completion of this session, participants should be able to:
• discuss the effects of pregnancy on the activity of rheumatic
diseases
• describe the challenging management issues unique to
pregnancy
B301
Pulmonary Manifestations of Rheumatic Disease (065)
Speaker: Paul F. Dellaripa, MD; Brigham and Women’s Hospital;
Boston, MA
Upon completion of this session, participants should be able to:
• identify emerging concepts regarding the pathophysiology of
inflammation and fibrosis in autoimmune lung disease
• determine the appropriate use of diagnostic tests in
the evaluation of patients with rheumatic disorders and
autoimmune lung disease
• discuss the limits of traditional therapeutic options and
possible emerging therapies in managing autoimmune lung
disease
B302
Rheumatoid Arthritis: Biological Agents (066) PS
Speaker: Larry W. Moreland, MD; University of Pittsburgh
Medical Center; Pittsburgh, PA
Upon completion of this session, participants should be able to:
• identify biologic agents in use for the treatment of rheumatoid
arthritis
• describe the risk/benefit profiles of biologic agents
• discuss the emerging biologics and their advantages for the
therapeutic algorithm
96
2010 Program Book